|
|
- 2018
国产多西他赛单药治疗晚期乳腺癌的疗效及安全性
|
Abstract:
| [1] | Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer[J]. J Clin Oncol, 2001, 19(22): 4216-4223. |
| [2] | Rd BH. Single-agent docetaxel(Taxotere)in randomized phase III trials[J]. Semin Oncol, 1999, 26(9): 1-6. |
| [3] | Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer[J]. J Clin Oncol, 2005, 23(24): 5542-5551. |
| [4] | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30. |
| [5] | Early Breast Cancer Trialists Collaborative Group(EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials[J]. Lancet, 2005, 365(9472): 1687-1717. |
| [6] | Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer[J]. Cochrane Database Syst Rev, 2009, 2(2). Doi:10.1002/14651858.CD-003372 pub3. |
| [7] | Seidman AD, Tiersten A, Hudis C, et al. Phase Ⅱ trial of paclitaxel by 3- hour infusion as initial and salvage chemotherapy for metastatic breast cancer[J]. J Clin Oncol, 1995, 13(10): 2575-2581. |
| [8] | National Cancer Institute. Common Terminology Criteria for Adverse Events v.4.0(CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed June 14, 2011. |
| [9] | Nabholtz JM, Tonkin K, Smylie M, et al. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?[J]. Expert Opin Pharmaco, 2000, 1(2): 187-206. |
| [10] | Sj？str？m J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group[J]. Eur J Cancer, 1999, 35(8): 1194-1201. |
| [11] | Brodowicz T, Koestler WJ, Tomek S, et al. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer[J]. Anti-Cancer Drugs, 2000, 11(3): 149-153. |
| [12] | Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy[J]. J Clin Oncol, 1999, 17(5): 1413-1424. |
| [13] | Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure[J]. Br J Cancer, 2002, 87(11): 1210-1215. |
| [14] | Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment[J]. J Clin Oncol, 1998, 16(10): 3426-3432. |
| [15] | Schwartz JR. Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?[J]. J Oncol Pharm Practice, 2012, 18(2): 250-256. |
| [16] | Chouhan JD, Herrington JD. Single premedication dose of dexamethasone 20 mg IV before docetaxel administration[J]. J Oncol Pharm Practice, 2010, 17(3): 155-159. |
| [17] | Cardoso F, Costa A, Senkus E, et al. 3rd ESMO International Consensus Guidelines for Advanced Breast Cancer(ABC 3)[J]. Ann Oncol, 2017, 28(1): 16-33. |
| [18] | Eisenhauer EA,Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. |
| [19] | Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines[J]. Cancer Chemother Pharmacol, 1992, 30(6): 444-450. |
| [20] | Harvey V, Mouridsen H, Semiglazov V, et al. Phase Ⅲ trial comparing three doses of docetaxel for second-1ine treatment of advanced breast cancer[J]. J Clin Oncol, 2006, 24(31): 4963-4970. |
| [21] | Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer[J]. Drugs, 2000, 59(3): 621-651. |
| [22] | 王子平, 孙燕, 张湘茹, 等. 多西他赛治疗晚期乳腺癌的临床研究[J]. 中华肿瘤杂志, 2006, 28(6): 468-470. WANG Ziping, SUN Yan, ZHANG Xiangru, et al. Docetaxel in the treatment of advanced breast cancer[J]. Chinese Journal of Oncology, 2006, 28(6): 468-470. |
| [23] | Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19): 4265-4274. |
| [24] | Bergh M, Magnusson K, Nilsson JL, et al. Contact allergenic activity of Tween 80 before and after air exposure[J]. Contact Dermatitis,1997, 37: 9-18. |
| [25] | 李海志, 徐沁甜, 宋毕清. 单次剂量地塞米松10 mg静注预防多西他赛副反应的安全性与可行性研究[J]. 中国现代医药杂志, 2016, 18(8): 63-64. |
